Q1 Beat Reinforces Profitability, but Rich Valuation Limits Upside

What happened

Q1 results showed Vyjuvek revenue jumping to $116.4M, net income of $56M, and a cash position nearing $1B, underscoring strong commercial execution. The article highlights upcoming catalysts including registrational data for KB803 and KB801, where KB801 is seen as a potential blockbuster in ophthalmology. However, the DeepValue master report cautions that the current ~$273 share price already reflects high expectations, trading at ~40x P/E and ~69x EV/EBITDA. While the quarter beat consensus and points to sustained franchise momentum, the finite U.S. DEB patient pool and slow ex-U.S. pricing negotiations remain risks to long-term growth. The pipeline's progress, though encouraging, is still largely pre-pivotal for major indications like CF, meaning the near-term valuation is heavily dependent on Vyjuvek's continued trajectory.

Implication

The strong Q1 print—with Vyjuvek revenue accelerating and profitability solidifying—suggests the base business is on a firmer footing than earlier models assumed, reducing downside tail risk. Still, at ~$273, the market is discounting a durable, high-margin Vyjuvek franchise plus meaningful pipeline success, and while KB801 in ophthalmology could be a genuine blockbuster, pivotal data is still out. The finite DEB patient pool and likely plateauing U.S. growth in coming quarters imply that revenue surprises may be harder to come by, while ex-U.S. contributions remain a slow burn subject to pricing negotiations. As a result, the investment case hinges on pipeline execution over the next 12-18 months; without clearer clinical outcomes, multiple expansion seems limited. Investors can take encouragement from the operational strength but should maintain discipline, considering trimming into strength around $310 or waiting for a pullback to the $220 area to add.

Thesis delta

The Q1 results modestly de-risk the near-term Vyjuvek growth trajectory, suggesting the bear case of imminent plateauing is less likely. However, the stock remains priced for perfection, and the core thesis—that valuation already embeds optimistic pipeline and ex-U.S. assumptions—is unchanged. Incremental positive data from KB801/803 could tilt the risk/reward, but for now the prudent stance is to hold, not add.